Table 1. Demographic characteristics in the two groups (rifaximin-α and placebo) [24].
| Rifaximin-α | Placebo | p-value | |
|---|---|---|---|
| Sex (male/female) | 31/5 | 14/4 | N/A |
| Age | 58.5 (33–68) | 52.5 (34–74) | 0.2 |
| Child Class B/C | 27/9 | 17/1 | N/A |
| MELD | 12 (6–25) | 9.5 (6–15) | 0.007 |
| Albumin g/l | 28.5 (21–40) | 32 (24–43) | 0.16 |
| Bilirubin μmol/l | 24 (8–166) | 16.5 (5–40) | 0.002 |
| Creatinine μmol/l | 60 (43–171) | 73 (44–146) | 0.53 |
| Platelets 109/l | 131 (27–562) | 151.5 (56–275) | 0.87 |
| Hemoglobin mmol/l | 7.6 (5.3–9.6) | 7.85 (5–9.8) | 0.36 |
| Alanine transaminase U/l | 25.5 (10–153) | 28 (15–56) | 0.79 |
| Alkaline phosphatase U/l | 121.5 (53–1200) | 146 (47–459) | 0.82 |
Values are given in median and minimum and maximum values, as they do not follow normal distribution, unless otherwise stated. MELD: Modified end stage liver disease score